Literature DB >> 22194586

Lung manifestations in an autopsy-based series of pulmonary or disseminated nontuberculous mycobacterial disease.

Meghan L O'Connell1, Kate E Birkenkamp1, David E Kleiner2, Les R Folio3, Steven M Holland1, Kenneth N Olivier4.   

Abstract

BACKGROUND: Comparisons of lung manifestations in primary pulmonary vs disseminated nontuberculous mycobacterial disease have not been well described. The clinical, histopathologic, and radiologic disease manifestations of primary pulmonary or disseminated nontuberculous mycobacterial disease were compared in an autopsy series.
METHODS: Medical and microbiologic records, autopsy reports, histopathologic slides of the lungs, and chest CT scans were reviewed on patients at the National Institutes of Health with nontuberculous mycobacterial disease who died between 1996 and 2010.
RESULTS: The 11 patients with primary pulmonary nontuberculous mycobacterial disease were predominantly female (n = 9), with symptom onset at median 50 (range 35, 71) years and time from onset until death of 12 (3, 34) years. Bronchiectasis with cavity formation and necrotizing bronchocentric granulomatous inflammation predominated but extrapulmonary infection was absent. The five patients with disseminated disease and systemic immune defects were all men with age at onset of 2 (0.33, 33) years and time from onset of disease until death of 9 (1, 31) years. Miliary nodules and/or consolidation with poorly formed granulomatous inflammation were noted in the three disseminated patients with mycobacterial lung involvement. Significant extrapulmonary infection was noted in all five with a relative paucity of lung findings.
CONCLUSIONS: Nontuberculous mycobacteria can cause progressive, fatal disease. Primary pulmonary disease is bronchocentric and lacks extrathoracic infection consistent with impaired airway surface defenses. In contrast, fatal disseminated infections involving the lung have hematogenous spread, extensive extrathoracic disease, and a distinct pulmonary histopathology consistent with systemic immune dysfunction.

Entities:  

Mesh:

Year:  2011        PMID: 22194586      PMCID: PMC3342780          DOI: 10.1378/chest.11-0425

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  23 in total

1.  Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems.

Authors:  D Rebecca Prevots; Pamela A Shaw; Daniel Strickland; Lisa A Jackson; Marsha A Raebel; Mary Ann Blosky; Ruben Montes de Oca; Yvonne R Shea; Amy E Seitz; Steven M Holland; Kenneth N Olivier
Journal:  Am J Respir Crit Care Med       Date:  2010-06-10       Impact factor: 21.405

2.  Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.

Authors:  Kenneth N Olivier; David J Weber; Richard J Wallace; Ali R Faiz; Ji-Hyun Lee; Yansheng Zhang; Barbara A Brown-Elliot; Allison Handler; Rebecca W Wilson; Michael S Schechter; Lloyd J Edwards; Subha Chakraborti; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2002-11-14       Impact factor: 21.405

3.  Non-tuberculous mycobacterial lung infection complicated by chronic necrotising pulmonary aspergillosis.

Authors:  I Hafeez; M F Muers; S A Murphy; E G Evans; R C Barton; P McWhinney
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

4.  Primary ciliary dyskinesia: diagnostic and phenotypic features.

Authors:  Peadar G Noone; Margaret W Leigh; Aruna Sannuti; Susan L Minnix; Johnny L Carson; Milan Hazucha; Maimoona A Zariwala; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2003-12-04       Impact factor: 21.405

5.  Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV-negative patients: five-year follow-up of patients receiving standardised treatment.

Authors: 
Journal:  Int J Tuberc Lung Dis       Date:  2002-07       Impact factor: 2.373

6.  The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation.

Authors:  Jordan S Orange; Ashish Jain; Zuhair K Ballas; Lynda C Schneider; Raif S Geha; Francisco A Bonilla
Journal:  J Allergy Clin Immunol       Date:  2004-04       Impact factor: 10.793

7.  Nontuberculous mycobacterial pulmonary infection in immunocompetent patients: comparison of thin-section CT and histopathologic findings.

Authors:  Yeon Joo Jeong; Kyung Soo Lee; Won-Jung Koh; Joungho Han; Tae Sung Kim; O Jung Kwon
Journal:  Radiology       Date:  2004-04-29       Impact factor: 11.105

8.  Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome.

Authors:  Richard D Kim; David E Greenberg; Mary E Ehrmantraut; Shireen V Guide; Li Ding; Yvonne Shea; Margaret R Brown; Milica Chernick; Wendy K Steagall; Connie G Glasgow; JingPing Lin; Clara Jolley; Lynn Sorbara; Mark Raffeld; Suvimol Hill; Nilo Avila; Vandana Sachdev; Lisa A Barnhart; Victoria L Anderson; Reginald Claypool; Dianne M Hilligoss; Mary Garofalo; Alan Fitzgerald; Sandra Anaya-O'Brien; Dirk Darnell; Rosamma DeCastro; Heather M Menning; Stacy M Ricklefs; Stephen F Porcella; Kenneth N Olivier; Joel Moss; Steven M Holland
Journal:  Am J Respir Crit Care Med       Date:  2008-08-14       Impact factor: 21.405

Review 9.  Susceptibility to nontuberculous mycobacterial lung disease.

Authors:  P Sexton; A C Harrison
Journal:  Eur Respir J       Date:  2008-06       Impact factor: 16.671

10.  Pathological findings of bronchiectases caused by Mycobacterium avium intracellulare complex.

Authors:  Jiro Fujita; Yuji Ohtsuki; Eriko Shigeto; Ichizo Suemitsu; Ichiro Yamadori; Shuji Bandoh; Masahiro Shiode; Kazutaka Nishimura; Takeshi Hirayama; Toshiharu Matsushima; Hajime Fukunaga; Toshihiko Ishida
Journal:  Respir Med       Date:  2003-08       Impact factor: 3.415

View more
  16 in total

1.  Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population.

Authors:  Theodore K Marras; Christopher Vinnard; Quanwu Zhang; Keith Hamilton; Jennifer Adjemian; Gina Eagle; Raymond Zhang; Engels Chou; Kenneth N Olivier
Journal:  Respir Med       Date:  2018-10-22       Impact factor: 3.415

2.  Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk.

Authors:  Jennifer Adjemian; Kenneth N Olivier; D Rebecca Prevots
Journal:  Am J Respir Crit Care Med       Date:  2014-09-01       Impact factor: 21.405

3.  Clonal Diversification and Changes in Lipid Traits and Colony Morphology in Mycobacterium abscessus Clinical Isolates.

Authors:  In Kwon Park; Amy P Hsu; Hervé Tettelin; Shamira J Shallom; Steven K Drake; Li Ding; Un-In Wu; Nick Adamo; D Rebecca Prevots; Kenneth N Olivier; Steven M Holland; Elizabeth P Sampaio; Adrian M Zelazny
Journal:  J Clin Microbiol       Date:  2015-08-19       Impact factor: 5.948

4.  Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease.

Authors:  Kenneth N Olivier; David E Griffith; Gina Eagle; John P McGinnis; Liza Micioni; Keith Liu; Charles L Daley; Kevin L Winthrop; Stephen Ruoss; Doreen J Addrizzo-Harris; Patrick A Flume; Daniel Dorgan; Matthias Salathe; Barbara A Brown-Elliott; Renu Gupta; Richard J Wallace
Journal:  Am J Respir Crit Care Med       Date:  2017-03-15       Impact factor: 21.405

Review 5.  The Many Hosts of Mycobacteria 8 (MHM8): A conference report.

Authors:  Michelle H Larsen; Karen Lacourciere; Tina M Parker; Alison Kraigsley; Jacqueline M Achkar; Linda B Adams; Kathryn M Dupnik; Luanne Hall-Stoodley; Travis Hartman; Carly Kanipe; Sherry L Kurtz; Michele A Miller; Liliana C M Salvador; John S Spencer; Richard T Robinson
Journal:  Tuberculosis (Edinb)       Date:  2020-02-11       Impact factor: 3.131

6.  A Rabbit Model to Study Antibiotic Penetration at the Site of Infection for Nontuberculous Mycobacterial Lung Disease: Macrolide Case Study.

Authors:  Firat Kaya; Jacqueline P Ernest; Katherine LoMauro; Martin Gengenbacher; Abdeldjalil Madani; Wassihun Wedajo Aragaw; Matthew D Zimmerman; Jansy P Sarathy; Nadine Alvarez; Isaac Daudelin; Han Wang; Faye Lanni; Danielle M Weiner; Laura E Via; Clifton E Barry; Kenneth N Olivier; Thomas Dick; Brendan K Podell; Radojka M Savic; Véronique Dartois
Journal:  Antimicrob Agents Chemother       Date:  2022-01-31       Impact factor: 5.938

7.  Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease.

Authors:  Kenneth N Olivier; Pamela A Shaw; Tanya S Glaser; Darshana Bhattacharyya; Michelle Fleshner; Carmen C Brewer; Christopher K Zalewski; Les R Folio; Jenifer R Siegelman; Shamira Shallom; In Kwon Park; Elizabeth P Sampaio; Adrian M Zelazny; Steven M Holland; D Rebecca Prevots
Journal:  Ann Am Thorac Soc       Date:  2014-01

8.  Abnormal nasal nitric oxide production, ciliary beat frequency, and Toll-like receptor response in pulmonary nontuberculous mycobacterial disease epithelium.

Authors:  Cedar J Fowler; Kenneth N Olivier; Janice M Leung; Caroline C Smith; Andrea G Huth; Heather Root; Douglas B Kuhns; Carolea Logun; Adrian Zelazny; Cathleen A Frein; Janine Daub; Carissa Haney; James H Shelhamer; Clare E Bryant; Steven M Holland
Journal:  Am J Respir Crit Care Med       Date:  2013-06-15       Impact factor: 21.405

Review 9.  Pulmonary Disease Due to Nontuberculous Mycobacteria: Current State and New Insights.

Authors:  Pamela J McShane; Jeffrey Glassroth
Journal:  Chest       Date:  2015-12       Impact factor: 9.410

10.  A Rhesus Macaque Model of Pulmonary Nontuberculous Mycobacterial Disease.

Authors:  Kevin Winthrop; Andrea Rivera; Flora Engelmann; Sasha Rose; Anne Lewis; Jennifer Ku; Luiz Bermudez; Ilhem Messaoudi
Journal:  Am J Respir Cell Mol Biol       Date:  2016-02       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.